研究单位：[1]Juventas Cell Therapy Ltd.[2]Tongji Hospital, Tongji Medical College of HUST[3]Fujian Medical University Union Hospital
研究目的：
The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.
